Skip Navigation

Cardiovascular Research 2000 45(2):339-350; doi:10.1016/S0008-6363(99)00353-3
© 2000 by European Society of Cardiology
This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Ghosh, S.
Right arrow Articles by Galiñanes, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ghosh, S.
Right arrow Articles by Galiñanes, M.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 2000, European Society of Cardiology

Preconditioning the human myocardium by simulated ischemia: studies on the early and delayed protection

Sudip Ghosha, Nicholas B Standenb and Manuel Galiñanesa,*

aDivision of Cardiac Surgery, Department of Surgery, University of Leicester, Glenfield Hospital, Leicester LE3 9QP, UK
bDepartment of Cell Physiology and Pharmacology, University of Leicester, Leicester LE1 7RH, UK

* Corresponding author

Received 1 July 1999; accepted 10 September 1999


    Abstract
 Top
 Abstract
 1 Introduction
 2 Methods
 3 Results
 4 Discussion
 5 Second window of...
 References
 
Background: There are data supporting the existence of ischemic preconditioning in man. This study investigated the most effective preconditioning protocol for the human myocardium and whether the second window of ischemic preconditioning (24 h) is as protective as the first window (≤2 h). Methods and results: Right atrial appendages (n=6/group) obtained during coronary bypass surgery were prepared and superfused with normoxic and normothermic Krebs–Henseleit solution. After 30 min stabilisation, muscles were subjected to various preconditioning protocols followed by 90 min ischemia and 120 min reperfusion. At the end of each protocol, the leakage of creatinine kinase (CK, U/g wet wt) and the reduction of MTT to insoluble formazan dye (OD/mg wet wt), an index of cell viability, were measured. In study 1, preconditioning was induced by 2, 3, 5 and 10 min of ischemia followed by 5 min reperfusion. In study 2, 1–4 cycles of 2 or 5 min ischemia–5 min reperfusion were applied. In study 3, preconditioning was induced by 5 min ischemia–5 min reperfusion followed by 1, 2, 3 or 4 h reperfusion before the subsequent 90 min ischemia. In study 4, preconditioning with 5 min ischemia followed by 5 min reperfusion either immediately preceded 30 or 90 min ischemia/120 min reperfusion or was applied 24 h before. In study 1 and 2, optimal protection was achieved with 5 min or two cycles of 2 min preconditioning ischemia (CK=3.06±0.31 and 2.89±0.02; MTT=0.56±0.05 and 0.47±0.09, respectively vs. CK=5.56±0.52 and MTT=0.18±0.04 in ischemia alone group; P<0.05). In study 3, protection was observed 2 h after preconditioning (CK=3.43±0.22 and MTT=0.46±0.09; P<0.01 vs. ischemia alone group) but it was lost beyond 2 h (CK=6.30±0.56 and MTT=0.16±0.02 after 3 h; P=NS vs. ischemia alone group). In study 4, protection was observed 24 h following preconditioning when the atrial specimens were exposed to 30 min ischemia (CK=2.96±0.38 and MTT=0.61±0.01 vs. CK=4.56±0.26 and MTT=0.43±0.02 in ischemia alone group, P<0.05); however, when the period of ischemia was extended to 90 min the beneficial effect of preconditioning was lost (CK=10.28±0.5 and MTT=0.11±0.05 vs. CK=9.56±0.62 and MTT=0.104±0.05 in ischemia alone group, P=NS). Conclusions: In the isolated human myocardium maximal protection induced by preconditioning is achieved by a total 4–5 min ischemic stimulus, an effect that is lost beyond 2 h of its application. Two windows of protection were identified, the first (≤2 h) being more potent than the second (24 h).

KEYWORDS Ischemia; Preconditioning


    1 Introduction
 Top
 Abstract
 1 Introduction
 2 Methods
 3 Results
 4 Discussion
 5 Second window of...
 References
 
Brief periods of ischemia and reperfusion appear to protect the myocardium from a subsequent lethal ischemic injury. This phenomenon of ischemic preconditioning, originally described by Murry et al. [1], has been shown to exist in all animal species studied to date. There is now compelling evidence that it exists in humans. This evidence arises from in vitro experiments with human atrial trabeculae [2], ventricular trabeculae [3] and cultured ventricular myocytes [4], studies of patients undergoing planned procedures which invariably involve brief periods of ischemia such as percutaneous transluminal coronary angioplasty [5] and coronary bypass graft surgery [6]. Despite the wealth of information generated by these human studies, the most effective ischemic preconditioning protocol in man remains unknown.

In rats, rabbits, dogs and pigs, separation of the brief preconditioning ischemic episodes from the long occlusion by 60 to 120 min results in complete or nearly complete loss of protection. However, if the duration of this separation is extended to 24 to 72 h, the infarct size will be reduced again. Hence there appears to be a distinct first (early) as well as a second (delayed) phase of protection. There is no evidence that this biphasic mode of protection exists in humans.

Although studies during angioplasty have given evidence for ischemic preconditioning in man, clearly there are practical and ethical limitations on the extent to which such situations can be used to investigate the characteristics of preconditioning in the human myocardium. In contrast, in vitro preparations allow a wide range of experimental manipulations. The aims of the present study were to investigate the most effective preconditioning protocol in human myocardium and also the existence and potency of a second window of protection. To achieve this, we subjected to simulated ischemia isolated, sliced and superfused right atrial trabeculae obtained from patients undergoing elective cardiac surgery. CK leakage and MTT reduction, an index of cell viability, were measured to assess myocardial injury.


    2 Methods
 Top
 Abstract
 1 Introduction
 2 Methods
 3 Results
 4 Discussion
 5 Second window of...
 References
 
2.1 Experimental preparation
Experiments were performed on trabeculae obtained from the right atrial appendage of patients undergoing elective coronary artery surgery or aortic valve replacement. Patients were excluded if they had large atriums, atrial arrythmias, poor left ventricular function (ejection fractions <30%), right ventricular failure or were taking oral hypoglycaemic agents or opioid analgesia. Local ethical committee approval was obtained for the harvesting technique. The specimens were collected in oxygenated HEPES buffered solution at 4–5°C and immediately sectioned and prepared for study. Briefly, the appendage was mounted onto a ground glass plate with the epicardial surface faced down and then sliced using surgical skin graft blades (Shwann-Morton, UK) to a thickness of between 300 and 500 µm. The specimen and the slide were always kept moist throughout the procedure. The muscles (weight 30–50 mg) were then transferred to conical flasks (25 ml Erlenmeyer flasks, Duran, Astell Scientific, Kent, UK) containing 10 ml of oxygenated buffered solution. Following this, the flasks were placed in a shaking water bath maintained at 37°C. The oxygenation of the incubation medium was maintained by a continuous flow of 95% O2–5% CO2 gas mixture to obtain a PO2 between 25 and 30 kPa and a PCO2 between 6 and 6.5 kPa. The PO2, PCO2 and pH in the incubation medium were monitored by intermittent analyses of the effluent by using an automated blood gas analyser (model 855 Blood Gas System, Chiron Diagnostics) and the pH was kept between 7.36 and 7.45. For the induction of simulated ischemia, the medium was bubbled with 95% N2–5% CO2 (pH 6.80–7.00) and D-glucose removed (see below). In this preparation, tissue injury and viability were assessed (see below) but the atrium was not paced and the force developed was not measured.

2.2 Solutions
The incubation medium was prepared daily with de-ionized distilled water and contained (in mmol/l): NaCl (118), KCl (4.8), NaHCO3 (27.2), KH2PO4 (1), MgCl2 (1.2), CaCl2 (1.25), D-glucose (10) and HEPES (20). During simulated ischemia, to maintain a constant osmolarity, D-glucose was removed and substituted with 2-deoxy glucose (10 mmol/l). All reagents were obtained from Sigma.

2.3 Experimental protocols
After sectioning the atrium, the preparations were allowed to stabilise for 30 min and then randomly allocated to various protocols. In most studies simulated ischemia was induced for a period of 90 min followed by 120 min of reperfusion.

2.3.1 Study 1
In this study, the effect of the duration of the preconditioning ischemic period was investigated. The preparations (n=6/group) were preconditioned with 2, 3, 5 or 10 min of ischemia followed by 5 min of reperfusion before the 90 min long ischemic insult. Fig. 1 shows the time course for the six study groups.


Figure 1
View larger version (7K):
[in this window]
[in a new window]
[Download PowerPoint slide]
 
Fig. 1 Experimental protocols for Study 1. All groups were equilibrated for 30 min in aerobic conditions (37°C). Following this, the right atrial slices (n=6/group) were preconditioned (IP) with various periods of ischemia followed by 5 min reperfusion. The study groups were matched with an aerobic control and ischemia alone group.

 
2.3.2 Study 2
In this study, the effect of the number of cycles of ischemia–reperfusion for preconditioning was investigated. In study 2A, preconditioning was induced by 1 to 4 cycles of 2 min ischemia–5 min reperfusion (n=6/group), whereas in study 2B, preconditioning was induced by 1 to 3 cycles of 5 min ischemia–5 min reperfusion (n=6/group). Fig. 2 displays the time course for the two study groups.


Figure 2
View larger version (13K):
[in this window]
[in a new window]
[Download PowerPoint slide]
 
Fig. 2 Experimental protocols for Study 2A and 2B. Right atrial slices in all groups (n=6/group) were equilibrated for 30 min. In Study 2A, the slices were then preconditioned(IP) with 1–4 cycles of 2 min ischemia–5 min reperfusion before being subjected to 90 min of ischemia–120 min reperfusion. In Study 2B, after equilibration, the slices were subjected to 1–3 cycles of 5 min ischemia–5 min reperfusion preconditioning before the 90-min ischemic period.

 
2.3.3 Study 3
In this study, the duration of the initial protective effect of preconditioning (‘early protection’ or ‘first window of protection’) was investigated. The preparations (n=6/group) were preconditioned with the protocol attaining the greatest protection in studies 1 and 2; this was one single cycle of 5 min ischemia. Then the tissues were reperfused for 1, 2, 3, or 4 h before the 90 min of ischemia. Fig. 3 shows the experimental time course for the six study groups.


Figure 3
View larger version (9K):
[in this window]
[in a new window]
[Download PowerPoint slide]
 
Fig. 3 Experimental protocols for Study 3. Right atrial slices in all groups (n=6/group) were equilibrated for 30 min. The right atrial slices (n=6/group) were then subjected to 5 min preconditioning (IP). Following this, the study groups were reperfused for various time intervals before the 90 min ischemia–120 min reperfusion.

 
2.3.4 Study 4
In this study, the ‘delayed protection’ or ‘second window of protection’ was investigated. We have previously demonstrated in our laboratory [7] that the human right atrial preparation used in the present studies remains viable for at least 24 h but is more sensitive to ischemia following 24 h aerobic incubation. For this reason, two periods of ischemia, 30 min (Study 4A) and 90 min (Study 4B) were studied (n=6/group). Again the preconditioning protocol consisted of a single cycle of 5 min ischemia–5 min reperfusion. Fig. 4 shows the experimental time course.


Figure 4
View larger version (13K):
[in this window]
[in a new window]
[Download PowerPoint slide]
 
Fig. 4 Experimental protocols for Study 4. Right atrial slices in all groups (n=6/group) were equilibrated for 30 min. In study 4A, after equilibration, the slices were aerobically incubated for 24 h. The ‘first window’ group were then preconditioned (IP) with 5 min ischemia–5 min reperfusion before being subjected to 30 min ischemia–120 min reperfusion. The ‘second window’ group were preconditioned initially with 5 min ischemia–5 min reperfusion before the 24 h incubation and then immediately subjected to 30 min ischemia–120 min reperfusion. In study 4B, identical protocols were applied except the ischemic time was extended to 90 min.

 
2.4 Assessment of tissue injury and viability
At the end of each experimental protocol, tissue injury was determined by measuring the leakage of creatinine kinase (CK) into the incubation medium and tissue viability by the reduction of 3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyltetrazolium bromide (MTT) to blue formazan product.

2.4.1 CK leakage
The activity of CK leakage into the media during the reperfusion period (U/g wet wt) was assayed by a kinetic ultraviolet method based on the formation of NAD (Sigma Catalogue No. 1340-K).

2.4.2 MTT reduction
At the end of the experimental time, the tissue was loaded into a Falcon conical tube (15 ml, Becton Dickinson, New Jersey, USA) and 2 ml of phosphate buffer solution (0.05 M) containing MTT (1.25 mg/ml, 3 mM at final concentration) was added, incubated for 30 min at 37°C and then homogenized in 2 ml dimethyl sulfoxide (Homogenizer Ultra-Turrax T25, dispersing tool G8, IKA-Labortechnic, Staufen, Germany) at 9500 rpm for 1 min. The homogenate was then centrifuged at 1000 g for 10 min and 0.2 ml of the supernatant was dispensed into a 98-well flat-bottom microtiter plate (Nunc Brand Products, Denmark). After this, the absorbance was measured on a plate reader (Benchmark, Bio-Rad, CA, USA) at 550 nm and the results expressed as OD/mg wet wt.

2.5 Statistical analysis
All data are presented as mean±S.E.M. All values were compared by ANOVA with application of a post hoc Tukey's test. Statistical significance was assumed at the P<0.05 level.


    3 Results
 Top
 Abstract
 1 Introduction
 2 Methods
 3 Results
 4 Discussion
 5 Second window of...
 References
 
Samples were obtained from patients with stable ischemic heart disease or aortic valve disease undergoing elective coronary bypass grafting or aortic valve replacement. All samples entering the studies completed the applied experimental protocol and were included in the analysis.

3.1 Study 1 — effect of the duration of the preconditioning ischemic stimulus
As shown in Fig. 5Go, 90 min of ischemia resulted in a significant increase in CK leakage and a decrease in MTT reduction. An inverted bell shape curve was observed for CK leakage when various periods of ischemic preconditioning were applied. 2 min of ischemia was not protective; 3 min of ischemia was the minimum period required to achieve a significant reduction in CK leakage but maximal protection was obtained with 5 min ischemic preconditioning with mean CK leakage values not significantly different from those in the aerobic control group. Surprisingly, protection was lost when ischemic preconditioning was extended to 10 min.


Figure 5
View larger version (26K):
[in this window]
[in a new window]
[Download PowerPoint slide]
 
Fig. 5 Study of the effect of the duration of the preconditioning ischemic stimulus on the (A) leakage of creatinine kinase (CK) and (B) MTT reduction of right atrial slices (n=6/group). Data are expressed as mean±standard error of the mean of six experiments. *P<0.05 vs. ischemia alone group.

 
A mirror image to that seen for CK leakage was observed for MTT reduction. Thus, 5 min of ischemic preconditioning afforded maximal protection such that MTT reduction values were similar to those seen in the aerobic control group, and again, protection was lost when the duration of ischemia was less than 3 min or increased to 10 min.

3.2 Study 2 — effect of the number of cycles of preconditioning
Fig. 6 shows the results of preconditioning with increasing cycles of 2 min ischemia–5 min reperfusion. The results from CK leakage and MTT reduction show that maximal protection was obtained with two cycles of 2 min ischemia. Interestingly, in this study preconditioning with one cycle of 2 min ischemia resulted in a small but statistically significant decrease in CK leakage. This result contrasts with that observed in study 1 where the enzyme leakage resulting from preconditioning with 2 min ischemia was similar to the mean values of the ischemia alone group. This apparent contradictory result may be attributed, at least in part, to the greater CK leakage seen in the ischemia alone group in study 2, since the CK leakage mean values in the 2 min ischemic preconditioning groups were similar in both studies. Alternatively, it may suggest that CK leakage is more sensitive than MTT reduction in assessing tissue injury and that 2 min ischemia is in the threshold of protection by ischemic preconditioning, a possibility that would be supported by the absence of protection in terms of MTT reduction with 2 min of ischemic preconditioning in the two studies. As shown above, increasing the number of cycles and the total ischemic preconditioning period beyond 5 min reduced or abolished the protection seen in the results with CK leakage and MTT reduction.


Figure 6
View larger version (22K):
[in this window]
[in a new window]
[Download PowerPoint slide]
 
Fig. 6 Study of the number of preconditioning cycles (2 min ischemia–5 min reperfusion) on the (A) leakage of CK and (B) MTT reduction of right atrial slices (n=6/group). Data are expressed as mean±standard error of mean of six experiments. *P<0.05 vs. ischemia alone group.

 
Fig. 7 shows the results on CK leakage and MTT reduction of preconditioning with increasing numbers of cycles of 5 min ischemia–5 min reperfusion. Both CK leakage and MTT reduction demonstrate clearly that protection is lost beyond 5 min of ischemic preconditioning. Overall these studies show that to precondition the human atrial myocardium the most important factor is the total ischemic stimulus and not the number of cycles.


Figure 7
View larger version (21K):
[in this window]
[in a new window]
[Download PowerPoint slide]
 
Fig. 7 Study of the number of preconditioning cycles (5 min ischemia–5 min reperfusion) on the the (A) leakage of CK and (B) MTT reduction of right atrial slices (n=6/group). Data are expressed as mean±standard error of mean of six experiments. *P<0.05 vs. ischemia alone group.

 
3.3 Study 3 — first window of protection
Fig. 8 shows the results on CK leakage and MTT reduction when ischemic preconditioning of atrial myocardium is followed by various reperfusion periods before the 90 min ischemia and 120 min reperfusion. The results show that the protection induced by preconditioning with only 5 min of reperfusion is maintained when the interval between the preconditioning and ischemia is within 2 h and that the beneficial effect is lost when that interval is extended to 3 or more hours.


Figure 8
View larger version (27K):
[in this window]
[in a new window]
[Download PowerPoint slide]
 
Fig. 8 Study of the duration of the initial protective effect of preconditioning (first window) on the (A) leakage of CK and (B) MTT reduction of right atrial slices (n=6/group). Data are expressed as mean±standard error of mean of six experiments. *P<0.05 vs. ischemia alone group.

 
3.4 Study 4 — second window of protection
We have shown in previous studies that the right atrial preparation used in the present experiments is viable for at least 24 h; however, after this time the preparation is more susceptible to ischemia–reperfusion injury than when incubated for shorter periods (unpublished data). For this reason, in this study two different periods of ischemia, 30 (moderate ischemia) and 90 min (severe ischemia), were used to investigate the late or second window of protection of ischemic preconditioning.

Fig. 9 shows the results with 30 min ischemia. Ischemia alone caused a significant increase in CK leakage and decrease in MTT reduction when compared with the aerobic control group. Both the first and second window of protection gave a similar decrease in CK leakage and amelioration of MTT reduction.


Figure 9
View larger version (18K):
[in this window]
[in a new window]
[Download PowerPoint slide]
 
Fig. 9 Study of the effect of the ‘first and second window’ of preconditioning on the (A) leakage of CK and (B) MTT reduction of right atrial slices (n=6/group) when subjected to 30 min of ischemia. Data are expressed as mean±standard error of mean of six experiments. *P<0.05 vs. aerobic control group; {dagger}P<0.05 vs. ischemia alone group.

 
As shown in Fig. 10, extension of the period of ischemia to 90 min resulted in greater CK leakage and lower MTT reduction than with 30 min ischemia. As expected, the first window of preconditioning significantly improved CK leakage and MTT reduction, however, this beneficial effect was not seen with the second window of preconditioning and values were similar to those observed in the ischemia alone group.


Figure 10
View larger version (15K):
[in this window]
[in a new window]
[Download PowerPoint slide]
 
Fig. 10 Study of the effect of the ‘first and second window’ of preconditioning on the (A) leakage of CK and (B) MTT reduction of right atrial slices (n=6/group) when subjected to 90 min of ischemia. Data are expressed as mean±standard error of mean of six experiments. *P<0.05 vs. aerobic control group; {dagger}P<0.05 vs. ischemia alone group.

 

    4 Discussion
 Top
 Abstract
 1 Introduction
 2 Methods
 3 Results
 4 Discussion
 5 Second window of...
 References
 
The present studies have characterised the ischemic preconditioning phenomenon in the human myocardium and have disclosed the following important results: (i) there is a graded narrow window of protection by preconditioning with 4–5 min of ischemia being the most effective period, (ii) the number of preconditioning cycles in itself does not influence protection, and ((iii) as shown in other animal species, there are two windows of protection, the first (≤2 h) being more protective than the second (24 h). These results have significant clinical implications and warrant further discussion.

4.1 Intensity of the preconditioning stimulus
Our studies are the first to demonstrate that maximal protection of the human myocardium by ischemic preconditioning is obtained with an ischemic stimulus of 4–5 min. It was not surprising that shorter periods of ischemia resulted in a decrease or loss protection since studies in animals have shown that the ischemic period should be greater than 2 min to achieve protection [8,9].

However, the loss of protection with ischemic periods beyond 6 min was unexpected since several investigators have reported that 10 min of ischemia preconditions the heart of a number of animal species [10–12].

The findings that 4–5 min of ischemia is the optimal time for preconditioning is supported by studies performed in the course of percutaneous transluminal coronary angioplasty (PTCA) [13,14]. In these studies, coronary arteries are typically occluded for 2 min by balloon inflation with 5 min apart. Consistently in all studies the severity of myocardial ischemia, assessed by changes in S-T segment shifts and angina symptoms, are less during the second and third balloon inflation than during the first inflation. This suggests that a total of 4–6 min of ischemic preconditioning also confers maximal protection in the clinical setting.

The present studies have also shown a dose–response effect in preconditioning the human myocardium so that the phenomenon should be identified as a graded rather than an all-or-nothing event. It is worth noting that the time window of protection was confined to a limited period, between 3 and 6 min of ischemia, and therefore studies involving few ischemic times may give the false impression that preconditioning is an all-or-nothing phenomenon. This thesis is supported by studies on anesthetized pigs [15] and rabbits [16] where graded ischemia determined the extent of infarct size reduction. It is also worth noting that our findings are in agreement with those of Downey et al. [17] that preconditioning ischemia <2 min did not confer protection, indicating that preconditioning has a threshold somewhere between 2 and 5 min. Their explanation was that the threshold of protection reflects the duration of ischemia required to build up adenosine levels to the point where adenosine receptors are adequately populated. It should be mentioned however that preconditioning by repeated short periods of ischemia and reperfusion may have resulted in wash-out of tissue adenosine and that in fact adenosine may not have been raised sufficiently to reach the threshold of protection. If this is the case then the mechanism of protection induced by repeated short ischemic cycles should involve the stimulation of receptors other than or in addition to adenosine receptors. Indeed Goto et al. [11] has previously suggested that the threshold of protection by preconditioning can be obtained by the additive effect of the stimulation of several membrane receptors (i.e. adenosine receptors, {alpha}1-adrenoreceptors, bradykinin and opioid receptors).

Another finding of our study that may have clinical implications is the loss of protection when the preconditioning ischemic stimulus was extended to 10 min, a time that has been reported to elicit protection in several animal species. Thus, if our results are extrapolated to clinical situations it is possible that repeated occlusions of a coronary artery during PTCA or of the ascending aorta during cardiac surgery totalling 10 or more min of ischemia may result inadvertently in loss of protection.

4.2 Number of preconditioning cycles
The results in Figs. 6 and 7Go clearly demonstrate that the number of preconditioning cycles per se do not influence the outcome and that in fact protection is determined by the intensity of the ischemic stimulus. Clinical studies on preconditioning in the course of PTCA where changes in S-T segment shift and the severity of angina are reduced during the second and third coronary occlusion [5] may be the reflection of fulfilling the optimal ischemic stimulus (i.e. 4–6 min) rather than an effect directly promoted by the increasing number of ischemic cycles. Animal studies in which preconditioning was elicited by increasing the number of cycles but using cycles of one ischemic duration time only [1,18,19] cannot separate the effects of the number of preconditioning cycles from those corresponding to the total duration of ischemia and hence, do not support or refute the above suggestion. Therefore, our results argue the conventional wisdom that preconditioning can be made more effective by increasing the number of ischemic cycles. It should be emphasised however that this argument may apply to our model of ischemia–reperfusion and that it may not necessarily be valid for shorter or longer periods of ischemia or different degrees of severity of tissue injury.

4.3 First window of protection
To the best of our knowledge, our studies are also the first to demonstrate that classical preconditioning of the human myocardium, also known as the early or first window of preconditioning, is restricted to the initial 2 h following its application, and this has obvious clinical implications. A similar response has been reported in a variety of animal species [9,20,21] supporting the view that the underlying mechanisms of the first window of preconditioning may be identical in all species. Certainly, the stimulation of membrane receptors such as A1/A3 and {alpha}1-adrenoreceptors and the activation of protein kinase C and KATP channels have been shown to be involved in the majority of the animal species studied [11,22–25] and in man [3,26]. Our finding that preconditioning is a graded phenomenon is also compatible with the notion that a number of triggers could be activated to achieve protection.

The realization that preconditioning is a phenomenon probably shared by all mammalian species studied including man and the evidence that it maybe elicited through identical molecular pathways, it makes possible that the results obtained from laboratory based studies may be extrapolated to the clinical setting with a high degree of confidence.


    5 Second window of protection
 Top
 Abstract
 1 Introduction
 2 Methods
 3 Results
 4 Discussion
 5 Second window of...
 References
 
Our studies are again the first to demonstrate the existence of a second window of protection in the human myocardium. However, we showed that the second window is not as protective as the first window, a result that is consistent with other reports in anesthetized rabbits and dogs [27–29]. The issue is not without controversy and some investigators [30,31] have reported that in anesthetized rabbits preconditioning does not result in infarct size reduction if the ischemic insult is applied in the following 24 or 48 h. The reasons for these discrepancies are not entirely clear, but differences in the experimental preparations and protocols should be taken into account. Preliminary studies conducted in our laboratory showed that the extent of protection obtained in the second window of preconditioning was similar with one cycle and with repeated cycles of ischemia as long as the total ischemic stimulus was between 4 and 5 min (data not shown).

The contrast between the universal presence of the first window of protection and the controversial second window may suggest that the mechanism underlying the two windows are different. The cellular mechanisms underlying the second window are not fully understood at present. Some experimental evidence for the involvement of adenosine receptor stimulation and activation of protein kinase C (PKC) in the development of delayed protection has been reported in rabbits [32,33]. However, PKC could influence a host of other signal transduction pathways and it is possible that other protein kinase events play a role in the mechanism. Certainly, other end-effectors have been implicated in the second window. These include the intracellular antioxidant superoxide dismutase (SOD) [34], heat shock proteins [35] and nitric oxide synthetase [36]. At present, there is limited evidence to suggest that KATP channels are involved in the delayed phase of protection [37]. It is quite clear that further research is needed in this area.

5.1 Limitations of the study and clinical implications
The present work has several limitations. First, in our preparation ischemia was induced by removing O2 and nutrient substrate but toxic metabolites, usually accumulated during ischemia, freely diffused into the incubation media (simulated ischemia). We accept that there are important differences between this model and true ischemia, particularly in respect to the washout of ischemic metabolites and pH changes. Second, we used atrial tissue and any extrapolation to ventricular myocardium must be conducted with caution; however, Walker et al. [2] have suggested that identical protection can be obtained by preconditioning in both tissues. Third, right atrial specimens were obtained from patients subjected to medical treatments (e.g. nitrates, β-blockers, calcium antagonists) that potentially may themselves influence ischemia–reperfusion injury and the protection induced by preconditioning. Fourth, our model is an in vitro preparation and the results may not completely apply to the clinical setting, although the findings during coronary artery occlusion in the course of PTCA may suggest that protection by preconditioning can be achieved with similar protocols in both situations.

Our results have important clinical implications by revealing that the duration of the ischemic stimulus rather than the number of cycles is the most important element influencing myocardial protection by preconditioning. Furthermore, this protection is a graded phenomenon with maximal benefit with 4–5 min ischemic duration and reduction or loss of protection if the ischemic stimulus is extended beyond 5 min. We also have shown that the second window of protection by preconditioning is not as effective as the first window and that this may lessen its relevance as a potential therapeutical intervention. However, further studies may be required to confirm this latter finding.

Time for primary review 31 days.


    Acknowledgements
 
This study was supported in part by grants from The Wellcome Trust, British Heart Foundation, Link-up Charities, Glenfield Hospital NHS Trust, Rhone-Poulenc Rorer (UK) and the University of Leicester.


    References
 Top
 Abstract
 1 Introduction
 2 Methods
 3 Results
 4 Discussion
 5 Second window of...
 References
 

  1. Murry C.E., Jennings R.B., Reimer K.A. Preconditioning with ischemia: a delay of lethal injury in ischemic myocardium. Circulation (1986) 74:1124–1136.[Abstract/Free Full Text]
  2. Walker D.M., Walker J.M., Pugsley W.B., et al. Preconditioning in isolated superfused human muscle. J Moll Cell Cardiol (1995) 27:1349–1357.[CrossRef][Web of Science][Medline]
  3. Cleveland J.C. Jr., Wollmering M.M., Meldrum D.R., et al. Ischemic preconditioning in human and rat ventricle. Am. J. Physiol. (1996) 271:H1786–H1794.[Web of Science][Medline]
  4. Ikonomidis J.S., Tumiati L.C., Weisel R.D., et al. Preconditioning human ventricular cardiomyocytes with brief periods of simulated ischemia. Cardiovasc. Res (1994) 28:1285–1291.[Abstract/Free Full Text]
  5. Deutsch E., Berger M., Kussmaul W.G., et al. Adaptation to ischemia during percutaneous transluminal coronary angioplasty: clinical, haemodynamic and metabolic features. Circulation (1990) 82:2044–2051.[Abstract/Free Full Text]
  6. Yellon D.M., Alkhulaifi A.M., Pugsley W.B. Preconditioning the human myocardium. Lancet (1993) 342:276–277.[CrossRef][Web of Science][Medline]
  7. Galiñanes M., Ghosh S., Zhang J.G. Characterization of an in vitro model for the study of the short and prolonged effects of myocardial ischemia and reperfusion in man. J. Moll. Cell. Cardiol (1999) 31(6):A47. Abstract.[Web of Science]
  8. Miura T., Limura O. Infarct limitation by preconditioning: its phenomenological features and key role of adenosine. Cardiovasc Res. (1993) 27:36–42.[Free Full Text]
  9. Van Winkle D.M., Thornton J.D., Downey D.M., Downey J.M. The natural history of preconditioning: cardioprotection depends of duration of transient ischemia and time to subsequent ischemia. Coronary Artery Dis. (1991) 2:613–619.[Web of Science]
  10. Baxter G.F., Goma G.F., Yellon D.M. Characterization of the infarct-limiting effect of delayed preconditioning: time course and dose-dependency studies in rabbit myocardium. Basic Res. Cardiol. (1997) 92:159–167.[CrossRef][Web of Science][Medline]
  11. Goto M., Liu Y., Yang X.-M., et al. Role of bradykinin in protection of ischemic preconditioning in rabbit hearts. Circ Res. (1995) 77:611–621.[Abstract/Free Full Text]
  12. Strasser R., Arras M., Vogt A., et al. Preconditioning of porcine myocardium: how much ischemia is required for induction? What is its duration? Is a renewal effect possible? Circulation (1994) 909(Suppl_1):109. Abstract.
  13. Tomai F., Crea F., Gasparadone A. Ischemic preconditioning during coronary angioplasty is prevented by glibenclamide, a selective ATP-sensitive K+ channel blocker. Circulation (1994) 90:700–705.[Abstract/Free Full Text]
  14. Depouy P., Geschwind H., Pelle G., et al. Repeated coronary artery occlusions during routine balloon angioplasty do not induce myocardial preconditioning in humans. J Am Coll Cardiol. (1996) 27:1374–1380.[Abstract]
  15. Schulz R., Post H., Valhaus C., et al. Ischemic preconditioning in pigs: a graded phenomenon. Its relation to adenosine and bradykinin. Circulation (1998) 98:1022–1029.[Abstract/Free Full Text]
  16. Sandhu R., Diaz R.J., Mao G.D., Wilson G.J. Ischemic preconditioning: difference in protection and susceptibility to blockade with single versus multicycle transient ischemia. Circulation (1997) 96:984–995.[Abstract/Free Full Text]
  17. Van Winckle D.M., Thornton J., Downey D.M., Downey J.M. The natural history of preconditioning: cardioprotection depends on duration on duration of transient ischemia and time to subsequent ischemia. Coronary Art Dis (1991) 2:613–619.[Web of Science]
  18. Cohen M.V., Yang X.-M., Downey J.M. Conscious rabbits become tolerant to multiple episodes of ischemic preconditioning. Circ Res. (1994) 74:998–1004.[Abstract/Free Full Text]
  19. Yao Z., Gross G.J. A comparison of adenosine-induced cardioprotection and ischemic preconditioning in dogs. Efficacy, time course and role of KATP channels. Circulation (1994) 89:1229–1236.[Abstract/Free Full Text]
  20. Miura T., Adachi T., Ogawa T., et al. Myocardial infarct-size limiting effect of ischemic preconditioning: its natural decay and the effect of repetitive preconditioning. Cardiovasc Pathol. (1992) 1:147–154.[CrossRef]
  21. Murry C.E., Richard V.J., Jennings R.B., Reimer K.A. Myocardial protection is lost before contractile function recovers from ischemic preconditioning. Am. J. Physiol. (1991) 260:H796–H804.[Web of Science][Medline]
  22. Li Y., Kloner R.A. Does protein kinase C play a role in ischemic preconditioning in rat hearts? Am. J. Physiol. (1995) 268:H426–H431.[Web of Science][Medline]
  23. Auchampach J., Gross G.J. Adenosine A1 receptors. KATP channels and ischemic preconditioning in dogs. Am. J. Physiol. (1993) 264:H1327–H1336.[Web of Science][Medline]
  24. Schulz R., Rose J., Heusch G. Involvement of activation of ATP-dependent potassium channels in ischemic preconditioning in swine. Am J Physiol. (1994) 267:H1341–H1352.[Web of Science][Medline]
  25. Schultz J.E.L., Rose E., Yao Z., Gross G.J. Evidence for the involvement of opioid receptors in ischemic preconditioning in rat hearts. Am. J. Physiol. (1995) 268:H2157–H2161.[Web of Science][Medline]
  26. Cohen G., Shirai T., Weisel R.D., et al. Optimal myocardial preconditioning in a human model of ischemia and reperfusion. Circulation (1998) 98:184–196.[Free Full Text]
  27. Marber M.S., Latchman D.S., Walker J.M., Yellon D.M. Cardiac stress protein elevation 24 h after brief ischemia or heat stress is associated with resistance to myocardial infarction. Circulation (1993) 88:1264–1272.[Abstract/Free Full Text]
  28. Kuzuya T., Hoshida S., Yamashita N., et al. Delayed effects of sublethal ischemia on the acquisition of tolerance to ischemia. Circ Res. (1993) 72:1293–1299.[Abstract/Free Full Text]
  29. Yang X.-M., Baxter G.F., Heads R.J., et al. Infarct limitation in the second window of protection in a conscious rabbit model. Cardivasc. Res. (1996) 31:777–783.[Abstract/Free Full Text]
  30. Tanaka M., Fujiwara H., Yamasaki K., et al. Ischemic preconditioning elevates cardiac stress protein but does not limit infarct size 24 h or 48 h later in rabbit hearts. Am. J. Physiol. (1994) 267:H1476–H1482.[Web of Science][Medline]
  31. Qian Y.Z., Bernado N.L., Nayeem M.A., et al. Induction of 72-kDa heat shock protein does not produce a second window of ischemic preconditioning in rat heart. Am. J. Physiol. (1999) 276:H224–H234.[Web of Science][Medline]
  32. Baxter G.F., Goma F.M., Yellon D.M. Involvement of protein kinase C in the delayed cytoprotection following sublethal ischemia in rabbit myocardium. Br. J. Pharmacol. (1995) 115:222–224.[Web of Science][Medline]
  33. Baxter G.F., Mocanu M., Yellon D.M. Diacylglycerol treatment in vivo increases ischemic tolerance 24 h later in a rabbit model of myocardial infarction. J. Moll. Cell. Cardiol. (1996) 28:A19.[CrossRef]
  34. Yamashita N., Nishida M., Hoshida S. Induction of manganese superoxide dismutase in rat cardiac myocytes increases tolerance to hypoxia 24 h after preconditioning. J. Clin. Invest. (1994) 94:2193–2199.[Web of Science][Medline]
  35. Yellon D.M., Marber M.S. Hsp 70 in myocardial ischemia. Experimentia (1994) 50:1075–1084.[CrossRef][Web of Science][Medline]
  36. Parratt J.R., Szekeres L. Delayed protection of the heart against ischemia. Trends Pharmacol. Sci. (1995) 16:351–355.[CrossRef][Medline]
  37. Fryer R.M., Hsu A.K., Eells J.T., et al. Opioid-induced second window of cardioprotection. Potential role of mitochondrial KATP channels. Circ Res. (1999) 84:846–851.[Abstract/Free Full Text]

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Eur Heart JHome page
V. K. Lai, K.-L. Ang, W. Rathbone, N. J. Harvey, and M. Galinanes
Randomized controlled trial on the cardioprotective effect of bone marrow cells in patients undergoing coronary bypass graft surgery
Eur. Heart J., October 1, 2009; 30(19): 2354 - 2359.
[Abstract] [Full Text] [PDF]


Home page
Toxicol PatholHome page
E. Golomb, A. Nyska, and H. Schwalb
Occult Cardiotoxicity--Toxic Effects on Cardiac Ischemic Tolerance
Toxicol Pathol, August 1, 2009; 37(5): 572 - 593.
[Abstract] [Full Text] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
A. Elami, Z. Gavish, A. Korach, E. Houminer, A. Schneider, H. Schwalb, and A. Arav
Successful restoration of function of frozen and thawed isolated rat hearts
J. Thorac. Cardiovasc. Surg., March 1, 2008; 135(3): 666 - 672.
[Abstract] [Full Text] [PDF]


Home page
Toxicol PatholHome page
E. Golomb, A. Schneider, E. Houminer, J. Dunnick, G. Kissling, J. B. Borman, A. Nyska, and H. Schwalb
Occult Cardiotoxicity: Subtoxic Dosage of Bis(2-chloroethoxy)methane Impairs Cardiac Response to Simulated Ischemic Injury
Toxicol Pathol, April 1, 2007; 35(3): 383 - 387.
[Abstract] [Full Text] [PDF]


Home page
J. Appl. Physiol.Home page
G. Martou, C. A. O'Blenes, N. Huang, S. E. McAllister, P. C. Neligan, H. Ashrafpour, C. Y. Pang, and J. E. Lipa
Development of an in vitro model for study of the efficacy of ischemic preconditioning in human skeletal muscle against ischemia-reperfusion injury
J Appl Physiol, November 1, 2006; 101(5): 1335 - 1342.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
A. Hassouna, M. Loubani, B. M. Matata, A. Fowler, N. B. Standen, and M. Galinanes
Mitochondrial dysfunction as the cause of the failure to precondition the diabetic human myocardium
Cardiovasc Res, February 1, 2006; 69(2): 450 - 458.
[Abstract] [Full Text] [PDF]


Home page
ICVTSHome page
J. S. Berg, B. O. Christensen, S. Aagaard, T. B.N. Christensen, D. A. Steinbruchel, and J. M. Hasenkam
Ischaemic preconditioning causes increased myocardial vascular resistance but no myocardial contractility changes in pigs after OPCAB
Interactive CardioVascular and Thoracic Surgery, June 1, 2005; 4(3): 207 - 211.
[Abstract] [Full Text] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
N. Ad, A. Schneider, I. Khaliulin, J. B. Borman, and H. Schwalb
Impaired mitochondrial response to simulated ischemic injury as a predictor of the development of atrial fibrillation after cardiac surgery: In vitro study in human myocardium
J. Thorac. Cardiovasc. Surg., January 1, 2005; 129(1): 41 - 45.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Cell Physiol.Home page
A. Hassouna, B. M. Matata, and M. Galinanes
PKC-{epsilon} is upstream and PKC-{alpha} is downstream of mitoKATP channels in the signal transduction pathway of ischemic preconditioning of human myocardium
Am J Physiol Cell Physiol, November 1, 2004; 287(5): C1418 - C1425.
[Abstract] [Full Text] [PDF]


Home page
J. Exp. Biol.Home page
H. A. Faust, A. K. Gamperl, and K. J. Rodnick
All rainbow trout (Oncorhynchus mykiss) are not created equal: intra-specific variation in cardiac hypoxia tolerance
J. Exp. Biol., February 22, 2004; 207(6): 1005 - 1015.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
M. Loubani, A. Hassouna, and M. Galinanes
Delayed preconditioning of the human myocardium: signal transduction and clinical implications
Cardiovasc Res, February 15, 2004; 61(3): 600 - 609.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
M. A. Deja, K. S. Golba, M. Kolowca, K. Widenka, J. Biernat, and S. Wos
Diazoxide provides protection to human myocardium in vitro that is concentration dependent
Ann. Thorac. Surg., January 1, 2004; 77(1): 226 - 232.
[Abstract] [Full Text] [PDF]


Home page
Eur. J. Cardiothorac. Surg.Home page
F. Nicolini, C. Beghi, C. Muscari, A. Agostinelli, A. M. Budillon, I. Spaggiari, and T. Gherli
Myocardial protection in adult cardiac surgery: current options and future challenges
Eur. J. Cardiothorac. Surg., December 1, 2003; 24(6): 986 - 993.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
A. Schneider, N. Ad, U. Izhar, I. Khaliulin, J. B. Borman, and H. Schwalb
Protection of myocardium by cyclosporin A and insulin: in vitro simulated ischemia study in human myocardium
Ann. Thorac. Surg., October 1, 2003; 76(4): 1240 - 1245.
[Abstract] [Full Text] [PDF]


Home page
Physiol. Rev.Home page
D. M. YELLON and J. M. DOWNEY
Preconditioning the Myocardium: From Cellular Physiology to Clinical Cardiology
Physiol Rev, October 1, 2003; 83(4): 1113 - 1151.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
B. Bartling, I. Friedrich, R.-E. Silber, and A. Simm
Ischemic preconditioning is not cardioprotective in senescent human myocardium
Ann. Thorac. Surg., July 1, 2003; 76(1): 105 - 111.
[Abstract] [Full Text] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
S. Ghosh and M. Galinanes
Protection of the human heart with ischemic preconditioning during cardiac surgery: role of cardiopulmonary bypass
J. Thorac. Cardiovasc. Surg., July 1, 2003; 126(1): 133 - 142.
[Abstract] [Full Text] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
M. Loubani, S. Ghosh, and M. Galinanes
The aging human myocardium: tolerance to ischemia and responsiveness to ischemic preconditioning
J. Thorac. Cardiovasc. Surg., July 1, 2003; 126(1): 143 - 147.
[Abstract] [Full Text] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
M. Loubani and M. Galinanes
Long-term administration of nicorandil abolishes ischemic and pharmacologic preconditioning of the human myocardium: Role of mitochondrial adenosine triphosphate-dependent potassium channels
J. Thorac. Cardiovasc. Surg., October 1, 2002; 124(4): 750 - 757.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
R. A Kloner, M. T Speakman, and K. Przyklenk
Ischemic preconditioning: a plea for rationally targeted clinical trials
Cardiovasc Res, August 15, 2002; 55(3): 526 - 533.
[Full Text] [PDF]


Home page
Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
A. K. Gamperl, A. E. Todgham, W. S. Parkhouse, R. Dill, and A. P. Farrell
Recovery of trout myocardial function following anoxia: preconditioning in a non-mammalian model
Am J Physiol Regulatory Integrative Comp Physiol, December 1, 2001; 281(6): R1755 - R1763.
[Abstract] [Full Text] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
M. Loubani and M. Galinanes
{{alpha}}1-Adrenoceptors during simulated ischemia and reoxygenation of the human myocardium: Effect of the dose and time of administration
J. Thorac. Cardiovasc. Surg., July 1, 2001; 122(1): 103 - 112.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Ghosh, S.
Right arrow Articles by Galiñanes, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ghosh, S.
Right arrow Articles by Galiñanes, M.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?